Jade Biosciences, Inc.(JBIO)

Biotechnology · Waltham, MA

$13.31-0.76 (-5.40%)

Delayed quote: Oct 6, 2026, 2:49 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T18:51:56.386Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:51:56.386Z.

Quote observation: 2026-10-06T18:49:58.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 810,044,896
Total debt · period ending 2026-06-30: 628,000
Cash · period ending 2026-06-30: 107,250,000
TTM operating EBITDA · period ending 2026-06-30: -164,702,000

FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

JBIO EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

JBIO Competitors' EV/EBITDA Ratio

JBIO

Jade Biosciences, Inc.

Current

Market Cap

$810.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARDX

Ardelyx, Inc.

vs JBIO

Market Cap

$812.73M

EV/EBITDA Ratio

N/A

TTM Avg

7.99x

3Y Avg

7.99x

5Y Avg

7.99x

INMD

InMode Ltd.

vs JBIO

Market Cap

$803.87M

EV/EBITDA Ratio

5.90x

TTM Avg

7.11x

3Y Avg

8.26x

5Y Avg

13.78x

GYRE

Gyre Therapeutics, Inc.

vs JBIO

Market Cap

$800.49M

EV/EBITDA Ratio

N/A

TTM Avg

76.03x

3Y Avg

57.10x

5Y Avg

57.10x

GERN

Geron Corporation

vs JBIO

Market Cap

$782.66M

EV/EBITDA Ratio

N/A

TTM Avg

800.36x

3Y Avg

800.36x

5Y Avg

800.36x

AHCO

AdaptHealth Corp.

vs JBIO

Market Cap

$785.71M

EV/EBITDA Ratio

6.63x

TTM Avg

5.45x

3Y Avg

14.30x

5Y Avg

12.03x

GLUE

Monte Rosa Therapeutics, Inc.

vs JBIO

Market Cap

$834.23M

EV/EBITDA Ratio

N/A

TTM Avg

45.75x

3Y Avg

45.75x

5Y Avg

45.75x

SANA

Sana Biotechnology, Inc.

vs JBIO

Market Cap

$783.39M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALMS

Alumis Inc.

vs JBIO

Market Cap

$838.44M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BBNX

Beta Bionics, Inc.

vs JBIO

Market Cap

$838.58M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Jade Biosciences, Inc. (JBIO)	$810.04M	N/A	N/A	N/A	N/A
Ardelyx, Inc. (ARDX)vs ›	$812.73M	N/A	7.99x	7.99x	7.99x
InMode Ltd. (INMD)vs ›	$803.87M	5.90x	7.11x	8.26x	13.78x
Gyre Therapeutics, Inc. (GYRE)vs ›	$800.49M	N/A	76.03x	57.10x	57.10x
Geron Corporation (GERN)vs ›	$782.66M	N/A	800.36x	800.36x	800.36x
AdaptHealth Corp. (AHCO)vs ›	$785.71M	6.63x	5.45x	14.30x	12.03x
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$834.23M	N/A	45.75x	45.75x	45.75x
Sana Biotechnology, Inc. (SANA)vs ›	$783.39M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$838.44M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$838.58M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics